Cognition Therapeutics

CGTX · NASDAQ

$0.7338+$0.0064 (+0.88%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $0.7274

CGTX analyst rating

BuyConsensus of 3 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy3
Hold0
Underperform0
Sell0

12-month price target · 5 analysts

Average $3.40 (+363.3% upside)

Low: $3.03
Now: $0.7338
High: $4.20

Upgrades and downgrades

The latest rating actions, newest first

CGTX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Chardan Capital	Mar 27, 2026	Maintains	Buy	$4.00	54%
HC Wainwright & Co.	Dec 4, 2025	Maintains	Buy	$3.00	43%
B. Riley Securities	Nov 21, 2025	Maintains	Buy	$2.00 → $3.00	23%
HC Wainwright & Co.	Nov 19, 2025	Maintains	Buy	$3.00	43%

The case for and against

Updated May 26, 2026

Bull case

Cognition Therapeutics is poised for success with its expanded access program for zervimesine in DLB, as patient feedback has been positive. However, investors should consider the potential risks of stock price volatility due to market fluctuations and overall economic conditions, as well as intellectual property risks and potential infringement claims from competitors or third parties. It is important for investors to closely monitor clinical trial results, regulatory decisions and market dynamics, and the strength of Cognition's patent protection.

Bear case

Cognition Therapeutics is currently a high-risk investment as their success heavily relies on the development of their sole therapeutic candidate, CT1812, which aims to treat numerous degenerative diseases. There is a high likelihood of failure in clinical trials or a lack of successful commercialization, which could negatively impact the company's business and financials. Furthermore, Cognition faces risks such as potential infringement claims, competition, and regulatory and financing uncertainties, all of which could hinder the approval and commercialization of their products.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.